Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neoantigen Polypeptide Vaccine-Second Affiliated Hospital of Guangzhou Medical University-solid tumor
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Guangzhou Medical University
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The Neoantigen Polypeptide Vaccine-Second Affiliated Hospital of Guangzhou Medical University-solid tumor is an investigational personalized cancer vaccine designed to treat advanced malignant solid neoplasms. The therapeutic approach involves identifying patient-specific tumor mutations through whole exome sequencing (WES) and RNA sequencing (RNA-seq). These identified neoantigens are then used to manufacture customized polypeptide sequences that serve as the active vaccine components. When administered, the vaccine is intended to stimulate the patient's immune system to recognize and attack tumor cells expressing these specific antigens. A Phase I clinical trial is evaluating the safety, tolerability, and preliminary efficacy of this vaccine in patients with advanced solid tumors, including colorectal cancer.
- Other names
- Neoantigen Polypeptide VaccineAnti-cancer Neoantigen Polypeptide Vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Neoantigen Polypeptide Vaccine-Second Affiliated Hospital of Guangzhou Medical University-solid tumor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neoantigen Polypeptide Vaccine-Second Affiliated Hospital of Guangzhou Medical University-solid tumor.